Free shipping on all orders over $ 500


Cat. No. M10894
Ubrogepant  Structure


Size Price Availability Quantity
1mg USD 500  USD500 In stock
5mg USD 1080  USD1080 In stock
10mg USD 1580  USD1580 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ubrogepant (MK-1602) is a novel oral calcitonin gene-associated peptide receptor (CGRP) antagonist with the potential to be used in acute migraine studies.

Chemical Information
Molecular Weight 549.54
Formula C29H26F3N5O3
CAS Number 1374248-77-7
Solubility (25°C) DMSO ≥ 200 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] No authors listed. Expert Opin Pharmacother. Ubrogepant

[2] No authors listed. Expert Opin Pharmacother. Ubrogepant

[3] Martina Curto, et al. Expert Opin Pharmacother. Ubrogepant for the treatment of migraine

[4] David W Dodick, et al. N Engl J Med. Ubrogepant for the Treatment of Migraine

[5] Richard B Lipton, et al. JAMA. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

Related CGRP Receptor Products
α-CGRP, human TFA

α-CGRP, human TFA is a regulatory neuropeptide of 37 amino acids. α-CGRP, human TFA can be used as a potent vasodilator.


Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research.


Eptinezumab is a human monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. Eptinezumab can be used for the prevention of migraine in adults.


Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine.


Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand.

Abmole Inhibitor Catalog

Keywords: Ubrogepant , MK-1602 supplier, CGRP Receptor, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.